Early Experience with Dabrafenib–Trametinib Combination in Patients with BRAF-Mutated Malignant Melanoma—A Single-Center Experience

Background Combination of dabrafenib–trametinib is one of the standard treatments in patients with BRAF-mutated advanced malignant melanoma (MM). Real-world data on the usage of this combination is scarce, especially from India. Here, we are reporting our early experience with the usage of this comb...

Full description

Bibliographic Details

Published in:	South Asian Journal of Cancer
Main Authors:	Sandip Ganguly, Joydeep Ghosh, Deepak Mishra, Gautam Biswas, Deepak Dabkara, Somanth Roy, Bivas Biswas
Format:	Article
Language:	English
Published:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2021-09-01
Subjects:	malignant melanoma braf mutation dabrafenib trametinib
Online Access:	http://www.thieme-connect.de/DOI/DOI?10.1055/s-0041-1736032